Cargando…
Recent strategies on targeted delivery of thrombolytics
Thrombus formed in blood vessel is a progressive process, which would lead to life-threatening thrombotic diseases such as ischemic stroke. Unlike other diseases, the recognition of thrombus is usually in the late stage where blood vessels are largely blocked. So acute thrombotic diseases have a nar...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shenyang Pharmaceutical University
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032080/ https://www.ncbi.nlm.nih.gov/pubmed/32104455 http://dx.doi.org/10.1016/j.ajps.2018.12.004 |
_version_ | 1783499497973743616 |
---|---|
author | Huang, Ting Li, Ni Gao, Jianqing |
author_facet | Huang, Ting Li, Ni Gao, Jianqing |
author_sort | Huang, Ting |
collection | PubMed |
description | Thrombus formed in blood vessel is a progressive process, which would lead to life-threatening thrombotic diseases such as ischemic stroke. Unlike other diseases, the recognition of thrombus is usually in the late stage where blood vessels are largely blocked. So acute thrombotic diseases have a narrow therapeutic window, and remain leading causes of morbidity and mortality, whereas current thrombolysis therapy has limited therapeutic effects and bleeding complications. Thrombolytic agents in unwanted sites would cause hemorrhage due to the activation of plasminogen. Moreover, untargeted thrombolysis therapy require large amounts of thrombolytic agents, which in return would enhance hemorrhage risk. To improve the efficiency while minimizing the adverse effects of traditional thrombolysis therapy, novel drug delivery systems have been investigated. Various targeting strategies including ultrasound and magnetic field directed targeting, and specific binding, have been designed to deliver thrombolytic drugs to the thrombotic sites. These strategies demonstrate promising results in reducing bleeding risk as well as allowing less dosage of thrombolytic drugs with lowered clot lysis time. In this review, we discuss recent progress on targeted delivery of thrombolytics, and summarize treatment advantages and shortcomings, potentially helping to further promote the development of targeted thrombolysis. |
format | Online Article Text |
id | pubmed-7032080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Shenyang Pharmaceutical University |
record_format | MEDLINE/PubMed |
spelling | pubmed-70320802020-02-26 Recent strategies on targeted delivery of thrombolytics Huang, Ting Li, Ni Gao, Jianqing Asian J Pharm Sci Review Article Thrombus formed in blood vessel is a progressive process, which would lead to life-threatening thrombotic diseases such as ischemic stroke. Unlike other diseases, the recognition of thrombus is usually in the late stage where blood vessels are largely blocked. So acute thrombotic diseases have a narrow therapeutic window, and remain leading causes of morbidity and mortality, whereas current thrombolysis therapy has limited therapeutic effects and bleeding complications. Thrombolytic agents in unwanted sites would cause hemorrhage due to the activation of plasminogen. Moreover, untargeted thrombolysis therapy require large amounts of thrombolytic agents, which in return would enhance hemorrhage risk. To improve the efficiency while minimizing the adverse effects of traditional thrombolysis therapy, novel drug delivery systems have been investigated. Various targeting strategies including ultrasound and magnetic field directed targeting, and specific binding, have been designed to deliver thrombolytic drugs to the thrombotic sites. These strategies demonstrate promising results in reducing bleeding risk as well as allowing less dosage of thrombolytic drugs with lowered clot lysis time. In this review, we discuss recent progress on targeted delivery of thrombolytics, and summarize treatment advantages and shortcomings, potentially helping to further promote the development of targeted thrombolysis. Shenyang Pharmaceutical University 2019-05 2019-02-04 /pmc/articles/PMC7032080/ /pubmed/32104455 http://dx.doi.org/10.1016/j.ajps.2018.12.004 Text en © 2019 Shenyang Pharmaceutical University. Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Huang, Ting Li, Ni Gao, Jianqing Recent strategies on targeted delivery of thrombolytics |
title | Recent strategies on targeted delivery of thrombolytics |
title_full | Recent strategies on targeted delivery of thrombolytics |
title_fullStr | Recent strategies on targeted delivery of thrombolytics |
title_full_unstemmed | Recent strategies on targeted delivery of thrombolytics |
title_short | Recent strategies on targeted delivery of thrombolytics |
title_sort | recent strategies on targeted delivery of thrombolytics |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032080/ https://www.ncbi.nlm.nih.gov/pubmed/32104455 http://dx.doi.org/10.1016/j.ajps.2018.12.004 |
work_keys_str_mv | AT huangting recentstrategiesontargeteddeliveryofthrombolytics AT lini recentstrategiesontargeteddeliveryofthrombolytics AT gaojianqing recentstrategiesontargeteddeliveryofthrombolytics |